Conavi Medical Reports Fiscal Year 2025 Results and Operational Highlights GlobeNewswire December 29, 2025 Next-Generation Novasight Hybrid(TM) System Submitted to U.S. FDA for 510(k) Clearance U.S. and European Class 1A Guidelines Reinforce Growing Adoption of Image-Guided PCI Peer-Reviewed Publications Highlight Clinical Importance of Intravascular Imaging Leadership Team Expanded to Support U.S. Commercial Launch and Operational […]

NEW YORK, NY / ACCESS Newswire / December 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oracle Corporation ("Oracle Corporation") (NYSE:ORCL) concerning possible violations of federal securities laws. What Happened? • On the evening of December 10, 2025, Oracle issued its second quarter earnings report for fiscal year

NEW YORK, NY / ACCESS Newswire / December 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Nutanix, Inc. ("Nutanix, Inc.") (NASDAQ:NTNX) concerning possible violations of federal securities laws. On November 25, 2025, after the market closed, Nutanix published first quarter fiscal 2026 revenue results that landed at the

NEW YORK, NY / ACCESS Newswire / December 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vistagen Therapeutics, Inc. ("Vistagen Therapeutics, Inc.") (NASDAQ:VTGN) concerning possible violations of federal securities laws. On December 17, 2025, before the market opened, Vistagen announced topline results from its PALISADE-3 Public Speaking Challenge

NEW YORK, NY / ACCESS Newswire / December 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oxford Industries, Inc. ("Oxford Industries, Inc.") (NYSE:OXM) concerning possible violations of federal securities laws. On December 10, 2025, after the market closed, Oxford published third quarter results for fiscal 2025 showing decreased

NEW YORK, NY / ACCESS Newswire / December 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alector, Inc. ("Alector, Inc.") (NASDAQ:ALEC) concerning possible violations of federal securities laws. On October 22, 2025, Alector announced results from its Phase 2 INFRONT-3 clinical trial evaluating latozinemab (AL001) in patients with

NEW YORK, NY / ACCESS Newswire / December 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Lennox International Inc. ("Lennox International Inc.") (NYSE:LII) concerning possible violations of federal securities laws. On October 22, 2025, Lennox published mixed third quarter 2025 financial results. Particularly, the Company disclosed that it

Vancouver, Canada–(Newsfile Corp. – December 29, 2025) – Turnium Technology Group Inc. (TSXV: TTGI) (FSE: E48) (“Turnium” or the “Company“), a global leader in Technology-as-a-Service (TaaS) and partner enablement services, provides an update regarding its previously announced non-binding letter of intent dated November 9, 2025 (the “LOI“) with Insentra Management Services Pty Ltd on behalf

New York, New York–(Newsfile Corp. – December 29, 2025) – DesignRush, a leading B2B platform, released its December 2025 ranking of the top web design agencies that help businesses improve digital experiences and reduce user drop-off. Recent data from Conviva shows that 91% of consumers encountered frustrating digital service issues in the past year. These

(NASDAQ:ZVRA), CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has executed an exclusive expanded access distribution agreement with Uniphar, an Ireland-based pharmaceutical services provider with a proven record